Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.64 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8980457 | 0.99 | HTR7 (0.63) | HTR7HTR6LMNAHTTSMN1; SMN2 | |
| SCHEMBL10035534 | 0.97 | HTR7 (0.63) | HTR7HTR6LMNAHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2138390 | 0.96 | HTR7 (0.62) | HTR7HTR6LMNAHTTSMN1; SMN2 | |
| SCHEMBL8982262 | 0.89 | HTR7 (0.51) | HTR7HTR6DRD2DRD3 | |
| SCHEMBL8982418 | 0.89 | ESR1 (0.52) | HTR7DRD3ALDH1A1 | |
| SCHEMBL8980091 | 0.80 | HTR7 (0.74) | HTR7HTR6DRD2 | |
| SCHEMBL4228351 | 0.80 | HTR7 (0.75) | HTR7HTR6TP53 | |
| SCHEMBL8979752 | 0.79 | HTR7 (0.72) | HTR7HTR6TP53 | |
| SCHEMBL8980207 | 0.79 | HTR7 (0.72) | HTR7HTR6DRD2 | |
| Hydrochloric Acid SCHEMBL4219449 | 0.79 | HTR7 (0.72) | HTR7HTR6DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188115-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-05-29 | — | — | US | disclosed |
| US-8188115-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-05-29 | — | — | US | disclosed |
| US-20090163542-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20090163542-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-7211585-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
| US-7211585-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163542-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | HTR7 1/4885HTR6 7/4885LMNA 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.